Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HABTE A YIMER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1881666477
CMS profile
175709
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$125,252.95

207 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 207 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HABTE A YIMER

NPI 1881666477 · CMS profile ID 175709

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 207 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881666477?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HABTE A YIMER, NPI 1881666477, CMS profile ID 175709. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 207 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881666477?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HABTE A YIMER, NPI 1881666477, CMS profile ID 175709. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 207 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881666477?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HABTE A YIMER, NPI 1881666477, CMS profile ID 175709, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 207 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1881666477?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

207 matching records · $125,252.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 207 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 207.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $5.5008/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078774124 CMS
PFIZER INC. $19.6208/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131355993 CMS
Janssen Biotech, Inc. $545.0008/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078774571 CMS
Karyopharm Therapeutics Inc. $23.7708/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145530217 CMS
ABBVIE INC. $6.1008/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106376520 CMS
Celgene Corporation $124.9908/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101089805 CMS
Celgene Corporation $15.0008/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101089807 CMS
Celgene Corporation $182.7708/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101089809 CMS
Blueprint Medicines Corporation $89.8008/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147450960 CMS
GlaxoSmithKline, LLC. $18.7308/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116283441 CMS
Daiichi Sankyo Inc. $26.5208/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089500710 CMS
E.R. Squibb & Sons, L.L.C. $14.5308/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101249083 CMS
Regeneron Healthcare Solutions, Inc. $29.3407/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114259394 CMS
Tempus AI, Inc $10.3807/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150177569 CMS
ADC Therapeutics America, Inc. $18.4507/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121186640 CMS
E.R. Squibb & Sons, L.L.C. $20.1907/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101249075 CMS
Tempus AI, Inc $19.4307/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150177567 CMS
ABBVIE INC. $8.9007/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106376518 CMS
AstraZeneca Pharmaceuticals LP $1,387.5007/01/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105704108 CMS
PFIZER INC. $2,880.0006/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132064340 CMS
PFIZER INC. $12.2606/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131813412 CMS
PFIZER INC. $3,275.0006/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131698385 CMS
AstraZeneca Pharmaceuticals LP $23.2806/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105500338 CMS
PFIZER INC. $101.0706/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131711163 CMS
Tempus AI, Inc $5.9006/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150177565 CMS
Janssen Biotech, Inc. $16.7506/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078773646 CMS
Novartis Pharmaceuticals Corporation $16.1906/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346124 CMS
E.R. Squibb & Sons, L.L.C. $10.4606/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101249069 CMS
E.R. Squibb & Sons, L.L.C. $0.5306/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101249071 CMS
Karyopharm Therapeutics Inc. $13.8706/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145530214 CMS
Regeneron Healthcare Solutions, Inc. $11.6806/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114259392 CMS
Tempus AI, Inc $2.9105/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150177563 CMS
Stemline Therapeutics Inc. $26.4705/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142960231 CMS
Lilly USA, LLC $12.8605/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134994624 CMS
Lilly USA, LLC $0.8805/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135018360 CMS
Astellas Pharma US Inc $19.4005/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139353931 CMS
AstraZeneca Pharmaceuticals LP $20.8605/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105237008 CMS
Tempus AI, Inc $29.2505/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150177561 CMS
ABBVIE INC. $15.1005/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106376516 CMS
BeiGene USA, Inc. $1,950.0005/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120860361 CMS
E.R. Squibb & Sons, L.L.C. $6.5605/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101249067 CMS
GENZYME CORPORATION $25.0205/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139757852 CMS
Regeneron Healthcare Solutions, Inc. $98.2205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114259390 CMS
Janssen Biotech, Inc. $39.1305/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078774275 CMS
Regeneron Healthcare Solutions, Inc. $21.2505/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114259388 CMS
Daiichi Sankyo Inc. $92.2305/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089500708 CMS
Janssen Biotech, Inc. $3,575.0005/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078773512 CMS
Regeneron Healthcare Solutions, Inc. $1.6404/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114259386 CMS
PFIZER INC. $6.3304/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131328351 CMS
Janssen Biotech, Inc. $89.9904/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078774433 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $127,125.98 173
PY2020 $92,724.94 80
PY2021 $115,277.59 96
PY2022 $116,510.07 117
PY2023 $141,512.36 166
PY2024 $125,252.95 207
PY2025 $215,549.74 280

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,090.48 3
PY2025 Principal investigator $2,007,791.41 284
PY2024 Recipient $27.90 1
PY2024 Principal investigator $1,843,460.13 436
PY2023 Recipient $1,436.45 1
PY2023 Principal investigator $1,798,931.94 342
PY2022 Principal investigator $1,855,755.26 479
PY2021 Principal investigator $2,282,477.17 440
PY2020 Recipient $4,990.93 3
PY2020 Principal investigator $1,917,455.73 372
PY2019 Recipient $14,099.40 2
PY2019 Principal investigator $665,216.98 463

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

287 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $144.00 12/31/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting No dispute reported 06/30/2026 1202533137
Principal investigator 1 Genentech, Inc. $5,600.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211649287
Principal investigator 1 Genentech, Inc. $13,519.00 12/22/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676663
Principal investigator 1 Genentech, Inc. $1,297.00 12/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211681204
Principal investigator 1 ABBVIE INC. $12,188.80 12/16/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202530598
Principal investigator 1 Genentech, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649361
Principal investigator 1 Genentech, Inc. $2,575.00 12/12/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676620
Principal investigator 1 Karyopharm Therapeutics Inc. $1,200.00 12/10/2025 Non-covered Recipient Entity
Texas Oncology, P.A
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1246665108
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 12/09/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335072
Principal investigator 1 BeOne Medicines Ltd. $1,500.00 12/09/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190341919
Principal investigator 1 BeOne Medicines Ltd. $451.00 12/09/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190341923
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 12/09/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343757
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 12/09/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343886
Principal investigator 1 ABBVIE INC. $19,840.95 12/04/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - NORTHEAST TEXAS
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202528556
Principal investigator 1 Epizyme, Inc. $41.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281790
Principal investigator 1 Epizyme, Inc. $41.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281792
Principal investigator 1 Epizyme, Inc. $27.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281794
Principal investigator 1 Epizyme, Inc. $29.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281796
Principal investigator 1 Epizyme, Inc. $27.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281798
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,900.00 12/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy No dispute reported 06/30/2026 1235993791
Principal investigator 1 Genentech, Inc. $14,213.00 12/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649359
Principal investigator 1 BeOne Medicines Ltd. $62,880.00 12/01/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330351
Principal investigator 1 BeOne Medicines Ltd. $78,600.00 12/01/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330353
Principal investigator 1 Genentech, Inc. $134,835.00 12/01/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676615
Principal investigator 1 Genentech, Inc. $42,915.00 12/01/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676639
Principal investigator 1 BeOne Medicines Ltd. $259.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335079
Principal investigator 1 BeOne Medicines Ltd. $1,411.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335084
Principal investigator 1 BeOne Medicines Ltd. $2,352.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343747
Principal investigator 1 BeOne Medicines Ltd. $499.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343754
Principal investigator 1 BeOne Medicines Ltd. $1,023.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343769
Principal investigator 1 BeOne Medicines Ltd. $414.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343783
Principal investigator 1 BeOne Medicines Ltd. $408.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343792
Principal investigator 1 BeOne Medicines Ltd. $1,411.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343797
Principal investigator 1 BeOne Medicines Ltd. $259.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343801
Principal investigator 1 BeOne Medicines Ltd. $1,411.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343804
Principal investigator 1 BeOne Medicines Ltd. $2,234.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343811
Principal investigator 1 BeOne Medicines Ltd. $499.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343819
Principal investigator 1 BeOne Medicines Ltd. $1,411.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343824
Principal investigator 1 BeOne Medicines Ltd. $2,234.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343833
Principal investigator 1 BeOne Medicines Ltd. $499.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343836
Principal investigator 1 BeOne Medicines Ltd. $499.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343847
Principal investigator 1 BeOne Medicines Ltd. $1,411.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343851
Principal investigator 1 BeOne Medicines Ltd. $259.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343859
Principal investigator 1 BeOne Medicines Ltd. $816.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343864
Principal investigator 1 BeOne Medicines Ltd. $1,023.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343870
Principal investigator 1 BeOne Medicines Ltd. $1,411.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343881
Principal investigator 1 BeOne Medicines Ltd. $1,023.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343889
Principal investigator 1 BeOne Medicines Ltd. $1,411.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343893
Principal investigator 1 BeOne Medicines Ltd. $1,023.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343902
Principal investigator 1 BeOne Medicines Ltd. $1,411.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343911
Principal investigator 1 BeOne Medicines Ltd. $259.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343919
Principal investigator 1 Genentech, Inc. $2,596.00 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649315
Principal investigator 1 Genentech, Inc. $4,998.00 11/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211681066
Principal investigator 1 Genentech, Inc. $4,998.00 11/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211681076
Principal investigator 1 Epizyme, Inc. $1,646.00 11/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281558
Principal investigator 1 BeOne Medicines Ltd. $259.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335075
Principal investigator 1 BeOne Medicines Ltd. $259.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343752
Principal investigator 1 BeOne Medicines Ltd. $2,234.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343761
Principal investigator 1 BeOne Medicines Ltd. $2,352.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343765
Principal investigator 1 BeOne Medicines Ltd. $499.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343807
Principal investigator 1 BeOne Medicines Ltd. $1,825.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343816
Principal investigator 1 BeOne Medicines Ltd. $2,352.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343828
Principal investigator 1 BeOne Medicines Ltd. $2,352.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343839
Principal investigator 1 BeOne Medicines Ltd. $259.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343855
Principal investigator 1 BeOne Medicines Ltd. $2,352.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343875
Principal investigator 1 BeOne Medicines Ltd. $2,352.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343905
Principal investigator 1 BeOne Medicines Ltd. $259.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343922
Principal investigator 1 BeOne Medicines Ltd. $408.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343927
Principal investigator 1 Genentech, Inc. $61.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649308
Principal investigator 1 Genentech, Inc. $47.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649311
Principal investigator 1 Genentech, Inc. $88.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649318
Principal investigator 1 Genentech, Inc. $55.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649323
Principal investigator 1 Genentech, Inc. $73.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649326
Principal investigator 1 Genentech, Inc. $66.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649335
Principal investigator 1 Genentech, Inc. $2,500.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649339
Principal investigator 1 Genentech, Inc. $47.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649343
Principal investigator 1 Genentech, Inc. $63.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211649348
Principal investigator 1 Janssen Research & Development, LLC $6,900.00 11/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma No dispute reported 06/30/2026 1175405643
Principal investigator 1 Janssen Research & Development, LLC $6,900.00 11/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma No dispute reported 06/30/2026 1175405760
Principal investigator 1 Janssen Research & Development, LLC $6,900.00 11/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma No dispute reported 06/30/2026 1175406809
Principal investigator 1 PFIZER INC. $887.00 11/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A DUALCOHORT OPENLABEL PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN AND CHP ACHP IN THE FRONTLINE TREATMENT OF SUBJECTS WITH PERIPHERAL TCELL LYMPHOMA PTCL WITH LESS THAN 10 CD30 EXPRESSION No dispute reported 06/30/2026 1228716347
Principal investigator 1 ABBVIE INC. $500.00 11/13/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202524059
Principal investigator 1 ABBVIE INC. $1,250.00 11/13/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202524061
Principal investigator 1 ABBVIE INC. $1,500.00 11/13/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202524063
Principal investigator 1 BeOne Medicines Ltd. $451.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190341927
Principal investigator 1 Epizyme, Inc. $41.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281570
Principal investigator 1 Epizyme, Inc. $27.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281584
Principal investigator 1 Epizyme, Inc. $1,646.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281590
Principal investigator 1 Epizyme, Inc. $4,991.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281592
Principal investigator 1 Epizyme, Inc. $1,646.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281560
Principal investigator 1 Epizyme, Inc. $41.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281572
Principal investigator 1 Epizyme, Inc. $41.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281576
Principal investigator 1 Epizyme, Inc. $27.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281578
Principal investigator 1 Epizyme, Inc. $27.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281580
Principal investigator 1 Epizyme, Inc. $1,646.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281586
Principal investigator 1 Epizyme, Inc. $1,125.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281588
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $253.02 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1223288129
Principal investigator 1 ABBVIE INC. $9,232.65 11/05/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - NORTHEAST TEXAS
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202522465
Principal investigator 1 Epizyme, Inc. $1,646.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281562
Principal investigator 1 Epizyme, Inc. $1,646.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281564
Principal investigator 1 Epizyme, Inc. $1,646.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281566
Principal investigator 1 Epizyme, Inc. $1,646.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281568
Principal investigator 1 Epizyme, Inc. $41.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281574
Principal investigator 1 Epizyme, Inc. $27.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281582
Principal investigator 1 Epizyme, Inc. $1,646.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281594
Principal investigator 1 Epizyme, Inc. $29.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281650
Principal investigator 1 Genentech, Inc. $4,998.00 11/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211681040
Principal investigator 1 Genentech, Inc. $1,125.00 11/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211681094
Principal investigator 1 Geron Corporation $1,250.00 10/29/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238896396
Principal investigator 1 BeOne Medicines Ltd. $408.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343780
Principal investigator 1 Genentech, Inc. $4,148.00 10/28/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676590
Principal investigator 1 Epizyme, Inc. $41.00 10/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281526
Principal investigator 1 Genentech, Inc. $1,375.00 10/22/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681380
Principal investigator 1 BeOne Medicines Ltd. $408.00 10/21/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343773
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 10/21/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343898
Principal investigator 1 Genentech, Inc. $24,500.00 10/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676582
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,250.00 10/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) No dispute reported 06/30/2026 1223287065
Principal investigator 1 ABBVIE INC. $1,063.00 10/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202517055
Principal investigator 1 Celgene Corporation $425.00 10/15/2025 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. No dispute reported 06/30/2026 1222304635
Principal investigator 1 PFIZER INC. $956.00 10/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A DUALCOHORT OPENLABEL PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN AND CHP ACHP IN THE FRONTLINE TREATMENT OF SUBJECTS WITH PERIPHERAL TCELL LYMPHOMA PTCL WITH LESS THAN 10 CD30 EXPRESSION No dispute reported 06/30/2026 1228716093
Recipient Novartis Pharmaceuticals Corporation $802.38 10/11/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291420
Principal investigator 1 ABBVIE INC. $3,078.49 10/09/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202514097
Principal investigator 1 ABBVIE INC. $9,975.15 10/09/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - NORTHEAST TEXAS
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202514683
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,689.40 10/08/2025 Non-covered Recipient Entity
Us Oncology Research
A Phase 3b randomized study of lenalidomide (CC-5013)plus rituximab maintenance therapy followed by lenalidomide singe-agent maintenance vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma No dispute reported 06/30/2026 1235992119
Principal investigator 1 BeOne Medicines Ltd. $408.00 10/07/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343777
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 10/07/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343842
Principal investigator 1 BeOne Medicines Ltd. $408.00 10/07/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190343915
Principal investigator 1 Epizyme, Inc. $41.00 10/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281528
Principal investigator 1 Epizyme, Inc. $29.00 10/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281530
Principal investigator 1 Epizyme, Inc. $1,646.00 10/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281532
Principal investigator 1 Epizyme, Inc. $1,646.00 10/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281534
Principal investigator 1 Epizyme, Inc. $27.00 10/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281536
Principal investigator 1 Epizyme, Inc. $41.00 10/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281538
Principal investigator 1 Epizyme, Inc. $27.00 10/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281540
Principal investigator 1 Epizyme, Inc. $27.00 10/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281542
Principal investigator 1 Epizyme, Inc. $1,646.00 10/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281544
Principal investigator 1 Genentech, Inc. $2,550.00 10/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680899
Principal investigator 1 Genentech, Inc. $1,125.00 10/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680945
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,588.52 10/01/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER PHARMACY
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190304143
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 09/25/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190336721
Principal investigator 1 BeOne Medicines Ltd. $62,880.00 09/25/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190336725
Principal investigator 1 Karyopharm Therapeutics Inc. $500.00 09/24/2025 Non-covered Recipient Entity
Texas Oncology, P.A
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1246665102
Principal investigator 1 Karyopharm Therapeutics Inc. $1,925.00 09/24/2025 Non-covered Recipient Entity
Texas Oncology, P.A
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1246665104
Principal investigator 1 Karyopharm Therapeutics Inc. $3,725.00 09/24/2025 Non-covered Recipient Entity
Texas Oncology, P.A
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1246665106
Principal investigator 1 Genentech, Inc. $2,588.00 09/23/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676574
Principal investigator 1 Epizyme, Inc. $27.00 09/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281362
Principal investigator 1 Epizyme, Inc. $41.00 09/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281380
Principal investigator 1 Epizyme, Inc. $41.00 09/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281390
Principal investigator 1 Epizyme, Inc. $41.00 09/18/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281378
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $54,280.00 09/18/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) No dispute reported 06/30/2026 1223285674
Principal investigator 1 Epizyme, Inc. $27.00 09/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281376
Principal investigator 1 Epizyme, Inc. $4,991.00 09/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281384
Principal investigator 1 Epizyme, Inc. $41.00 09/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281392
Principal investigator 1 Epizyme, Inc. $41.00 09/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281402
Principal investigator 1 Epizyme, Inc. $1,646.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281364
Principal investigator 1 Epizyme, Inc. $27.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281366
Principal investigator 1 Epizyme, Inc. $29.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281372
Principal investigator 1 Epizyme, Inc. $41.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281386
Principal investigator 1 Genentech, Inc. $432.00 09/12/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681298
Principal investigator 1 Genentech, Inc. $1,375.00 09/10/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681328
Principal investigator 1 ABBVIE INC. $16,186.50 09/04/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - NORTHEAST TEXAS
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202509582
Principal investigator 1 ABBVIE INC. $2,000.36 09/04/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202509668
Principal investigator 1 BeOne Medicines Ltd. $73,360.00 09/04/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190330081
Principal investigator 1 BeOne Medicines Ltd. $20,960.00 09/04/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190330083
Principal investigator 1 Epizyme, Inc. $27.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281368
Principal investigator 1 Epizyme, Inc. $1,646.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281370
Principal investigator 1 Epizyme, Inc. $1,646.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281374
Principal investigator 1 Epizyme, Inc. $29.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281382
Principal investigator 1 Epizyme, Inc. $4,991.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281388
Principal investigator 1 Epizyme, Inc. $27.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281394
Principal investigator 1 Epizyme, Inc. $1,646.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281396
Principal investigator 1 Epizyme, Inc. $1,125.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281398
Principal investigator 1 Epizyme, Inc. $1,646.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281400
Principal investigator 1 Epizyme, Inc. $1,646.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281404
Principal investigator 1 Genentech, Inc. $1,375.00 09/03/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681324
Principal investigator 1 Genentech, Inc. $1,375.00 09/03/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681326
Principal investigator 1 Genentech, Inc. $1,375.00 09/03/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681356
Principal investigator 1 BeOne Medicines Ltd. $125,760.00 09/02/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330319
Principal investigator 1 Genentech, Inc. $57.00 09/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680673
Principal investigator 1 Genentech, Inc. $57.00 09/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680813
Principal investigator 1 ABBVIE INC. $6,537.70 08/29/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202506573
Principal investigator 1 Epizyme, Inc. $1,646.00 08/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281280
Principal investigator 1 Epizyme, Inc. $1,646.00 08/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281282
Principal investigator 1 Genentech, Inc. $43,547.00 08/27/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676566
Principal investigator 1 Genentech, Inc. $153,385.00 08/11/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676533
Principal investigator 1 PFIZER INC. $1,125.00 08/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A DUALCOHORT OPENLABEL PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN AND CHP ACHP IN THE FRONTLINE TREATMENT OF SUBJECTS WITH PERIPHERAL TCELL LYMPHOMA PTCL WITH LESS THAN 10 CD30 EXPRESSION No dispute reported 06/30/2026 1228766648
Principal investigator 1 Genentech, Inc. $4,644.00 08/07/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676563
Principal investigator 1 ABBVIE INC. $24,420.15 08/06/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - NORTHEAST TEXAS
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202502452
Principal investigator 1 ABBVIE INC. $1,612.64 08/06/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202503383
Recipient Novartis Pharmaceuticals Corporation $126.05 08/05/2025 Covered Recipient Physician CABL001AUS08 No dispute reported 06/30/2026 1190292788
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,250.00 07/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 1223283224
Principal investigator 1 ABBVIE INC. $335.40 07/24/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202499546
Principal investigator 1 Genentech, Inc. $17,362.00 07/17/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676510
Principal investigator 1 ABBVIE INC. $1,063.00 07/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202498306
Principal investigator 1 PFIZER INC. $956.00 07/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A DUALCOHORT OPENLABEL PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN AND CHP ACHP IN THE FRONTLINE TREATMENT OF SUBJECTS WITH PERIPHERAL TCELL LYMPHOMA PTCL WITH LESS THAN 10 CD30 EXPRESSION No dispute reported 06/30/2026 1228750084
Principal investigator 1 Genentech, Inc. $1,125.00 07/09/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680867
Principal investigator 1 Janssen Research & Development, LLC $129.00 07/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma No dispute reported 06/30/2026 1175404722
Principal investigator 1 PFIZER INC. $1,043.00 07/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A DUALCOHORT OPENLABEL PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN AND CHP ACHP IN THE FRONTLINE TREATMENT OF SUBJECTS WITH PERIPHERAL TCELL LYMPHOMA PTCL WITH LESS THAN 10 CD30 EXPRESSION No dispute reported 06/30/2026 1228792153
Principal investigator 1 Karyopharm Therapeutics Inc. $1,125.00 07/03/2025 Non-covered Recipient Entity
USOR: TX Oncology Fort Worth
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246666776
Principal investigator 1 Karyopharm Therapeutics Inc. $1,125.00 07/03/2025 Non-covered Recipient Entity
USOR: TX Oncology Fort Worth
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246666784
Principal investigator 1 ABBVIE INC. $10,211.40 07/02/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - NORTHEAST TEXAS
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202493985
Principal investigator 1 ABBVIE INC. $1,612.64 07/02/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202494755
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 06/26/2025 Non-covered Recipient Entity
NE TX CAN & RESEARCH INSTITUTE
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342262
Principal investigator 1 Genentech, Inc. $27,415.00 06/26/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676461
Principal investigator 1 Epizyme, Inc. $2,324.00 06/18/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281270
Principal investigator 1 PFIZER INC. $887.00 06/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A DUALCOHORT OPENLABEL PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN AND CHP ACHP IN THE FRONTLINE TREATMENT OF SUBJECTS WITH PERIPHERAL TCELL LYMPHOMA PTCL WITH LESS THAN 10 CD30 EXPRESSION No dispute reported 06/30/2026 1228746187
Principal investigator 1 BeOne Medicines Ltd. $408.00 06/10/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190339264
Principal investigator 1 Epizyme, Inc. $1,723.00 06/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281272
Principal investigator 1 ABBVIE INC. $1,927.24 06/03/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202487753
Principal investigator 1 ABBVIE INC. $5,848.20 06/03/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - NORTHEAST TEXAS
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202488421
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 06/03/2025 Non-covered Recipient Entity
NE TX CAN & RESEARCH INSTITUTE
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342326
Principal investigator 1 BeOne Medicines Ltd. $41,920.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190330137
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190339268
Principal investigator 1 BeOne Medicines Ltd. $198.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190339272
Principal investigator 1 BeOne Medicines Ltd. $32.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190339276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $460.00 06/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 1223280534
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $460.00 06/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 1223280536
Principal investigator 1 ABBVIE INC. $750.00 05/27/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202486247
Principal investigator 1 Janssen Research & Development, LLC $6,900.00 05/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma No dispute reported 06/30/2026 1175407147
Principal investigator 1 Genentech, Inc. $1,297.00 05/09/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680005
Principal investigator 1 Genentech, Inc. $29,923.00 05/08/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676474
Principal investigator 1 Genentech, Inc. $88.00 05/08/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676488
Principal investigator 1 Genentech, Inc. $150,657.00 05/08/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211676493
Principal investigator 1 TAIHO ONCOLOGY, INC. $168.17 05/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211415261
Principal investigator 1 TAIHO ONCOLOGY, INC. $168.17 05/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211415992
Principal investigator 1 TAIHO ONCOLOGY, INC. $436.11 05/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211416686
Principal investigator 1 TAIHO ONCOLOGY, INC. $168.17 05/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211416688
Principal investigator 1 TAIHO ONCOLOGY, INC. $436.11 05/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211418089
Principal investigator 1 TAIHO ONCOLOGY, INC. $168.17 05/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211418091
Principal investigator 1 TAIHO ONCOLOGY, INC. $168.17 05/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211418093
Principal investigator 1 TAIHO ONCOLOGY, INC. $168.17 05/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211419513
Principal investigator 1 TAIHO ONCOLOGY, INC. $168.17 05/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211419515
Principal investigator 1 TAIHO ONCOLOGY, INC. $168.17 05/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211420251
Principal investigator 1 ABBVIE INC. $7,639.65 05/07/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - NORTHEAST TEXAS
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202483565
Principal investigator 1 ABBVIE INC. $1,710.14 05/07/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202483567
Principal investigator 1 AstraZeneca Pharmaceuticals LP $857.90 05/07/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185551257
Principal investigator 1 Epizyme, Inc. $5,764.00 04/30/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281182
Principal investigator 1 BeiGene, Ltd. $15,750.00 04/29/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321026
Principal investigator 1 BeiGene, Ltd. $1,250.00 04/29/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321028
Principal investigator 1 BeiGene, Ltd. $750.00 04/29/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321030
Principal investigator 1 Epizyme, Inc. $1,646.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280874
Principal investigator 1 Epizyme, Inc. $27.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280876
Principal investigator 1 Epizyme, Inc. $41.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281006
Principal investigator 1 Epizyme, Inc. $29.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281094
Principal investigator 1 Epizyme, Inc. $41.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281096
Principal investigator 1 Epizyme, Inc. $1,646.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281144
Principal investigator 1 Epizyme, Inc. $27.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281174
Principal investigator 1 Epizyme, Inc. $1,646.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281190
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,250.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 1223278700
Principal investigator 1 Genentech, Inc. $1,125.00 04/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680059
Principal investigator 1 Genentech, Inc. $1,125.00 04/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680091
Principal investigator 1 BeiGene, Ltd. $8,901.00 04/16/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321032
Principal investigator 1 ABBVIE INC. $1,063.00 04/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202476610
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $425.00 04/15/2025 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. No dispute reported 06/30/2026 1235993237
Principal investigator 1 PFIZER INC. $956.00 04/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A DUALCOHORT OPENLABEL PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN AND CHP ACHP IN THE FRONTLINE TREATMENT OF SUBJECTS WITH PERIPHERAL TCELL LYMPHOMA PTCL WITH LESS THAN 10 CD30 EXPRESSION No dispute reported 06/30/2026 1228748321
Principal investigator 1 BeiGene, Ltd. $1,528.00 04/08/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322850
Principal investigator 1 ABBVIE INC. $1,727.56 04/03/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202469679
Principal investigator 1 ABBVIE INC. $15,047.10 04/03/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - NORTHEAST TEXAS
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202469743
Principal investigator 1 Karyopharm Therapeutics Inc. $500.00 04/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1246665098
Principal investigator 1 Karyopharm Therapeutics Inc. $1,200.00 04/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1246665100
Principal investigator 1 ABBVIE INC. $1,250.00 04/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202468004
Principal investigator 1 Genentech, Inc. $22,646.16 04/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680057
Principal investigator 1 Genentech, Inc. $1,375.00 03/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681250
Principal investigator 1 BeiGene, Ltd. $2,551.00 03/25/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322846
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,522.00 03/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 1223276173
Principal investigator 1 ABBVIE INC. $1,975.99 03/07/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202461995
Principal investigator 1 Janssen Research & Development, LLC $129.00 03/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma No dispute reported 06/30/2026 1175404704
Principal investigator 1 Janssen Research & Development, LLC $6,900.00 03/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma No dispute reported 06/30/2026 1175407131
Principal investigator 1 BeiGene, Ltd. $31,440.00 02/27/2025 Non-covered Recipient Entity
NE TX CAN & RESEARCH INSTITUTE
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325284
Principal investigator 1 Genentech, Inc. $1,375.00 02/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681244
Principal investigator 1 BeiGene, Ltd. $5,122.00 02/25/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190325586
Principal investigator 1 PFIZER INC. $887.00 02/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A DUALCOHORT OPENLABEL PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN AND CHP ACHP IN THE FRONTLINE TREATMENT OF SUBJECTS WITH PERIPHERAL TCELL LYMPHOMA PTCL WITH LESS THAN 10 CD30 EXPRESSION No dispute reported 06/30/2026 1228747314
Principal investigator 1 Acerta Pharma LLC $21,045.29 02/12/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185551259
Principal investigator 1 Genentech, Inc. $2,028.00 02/12/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211679831
Principal investigator 1 BeiGene, Ltd. $8,506.00 02/11/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325568
Principal investigator 1 ABBVIE INC. $3,486.45 02/06/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202447819
Principal investigator 1 BeiGene, Ltd. $25,838.16 02/05/2025 Non-covered Recipient Entity
NE TX CAN & RESEARCH INSTITUTE
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323598
Principal investigator 1 Celgene Corporation $2,000.00 02/05/2025 Non-covered Recipient Entity
Us Oncology Res Llc
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. No dispute reported 06/30/2026 1222305662
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,250.00 02/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 1223274721
Principal investigator 1 BeiGene, Ltd. $4,079.00 01/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322848
Recipient Novartis Pharmaceuticals Corporation $162.05 01/28/2025 Covered Recipient Physician CABL001AUS08 No dispute reported 06/30/2026 1190291836
Principal investigator 1 BeiGene, Ltd. $47,160.00 01/22/2025 Non-covered Recipient Entity
NE TX CAN & RESEARCH INSTITUTE
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323650
Principal investigator 1 ABBVIE INC. $1,063.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202438587
Principal investigator 1 Amgen Inc. $2,550.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) No dispute reported 06/30/2026 1246649333
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $425.00 01/15/2025 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. No dispute reported 06/30/2026 1235993235
Principal investigator 1 PFIZER INC. $956.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A DUALCOHORT OPENLABEL PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN AND CHP ACHP IN THE FRONTLINE TREATMENT OF SUBJECTS WITH PERIPHERAL TCELL LYMPHOMA PTCL WITH LESS THAN 10 CD30 EXPRESSION No dispute reported 06/30/2026 1228750881
Principal investigator 1 Novartis Pharmaceuticals Corporation $59,068.22 01/01/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER PHARMACY
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190305067